Well, the stock seemed to hold that .80-ish range this week. I was a little surprised that we didn’t hover over $1 just on the covid19 developments. Always something holding us down. As we look to next week, I'm hoping that we get some kind solid update on the company's covid-19 vaccine efforts,as well as something about whether or not their diagnostic division will be able to produce a test kit. Jumping out of that basket, what about the S-1, Altucell closing, Olaregen, Regentys, and the NGIO uplisting? Oh, and if BP wants to swoop in an buy out NGIO for a nice price, that would be nice too.